Tm Bioscience posts "for sale" sign

Tm Bioscience, a Toronto-based developer of DNA-based genetic tests, is exploring a possible sale or merger. Company officials say they've been approached by interested parties, making it an "ideal time" to explore its options. They're showing every sign of looking for the best terms they can get, touting their revenue from existing tests and a pipeline of new products.

- read the report from The Globe and Mail for more

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.